Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
The AD/PD 2026 conference featured extensive scientific programming covering the latest advances in both Alzheimer's disease and Parkinson's disease research. This page details the major scientific sessions, key presentations, and notable findings from the conference[1].
Sessions on amyloid biology featured cutting-edge research into Amyloid Precursor Protein (APP) processing, amyloid-beta aggregation mechanisms, and therapeutic targeting of the amyloid pathway[2]. Key themes included:
Tau-focused sessions covered the spectrum of tau research from basic biology to clinical trials:
The neuroinflammation track explored the critical role of immune responses in neurodegenerative diseases:
Biomarker sessions showcased significant advances in fluid and imaging biomarkers:
Clinical trial sessions featured updates on disease-modifying therapies:
Alpha-synuclein sessions highlighted the central role of this protein in PD pathogenesis[3]:
Genetic sessions covered well-established and newly identified risk factors:
Mitochondrial research sessions explored energy metabolism in PD:
Clinical sessions addressed motor complications:
Sessions explored shared mechanisms across neurodegenerative diseases:
The conference featured keynote presentations from leading researchers in the field, covering fundamental insights and translational directions for both AD and PD research.
Extensive poster presentations provided opportunities for researchers to present detailed findings and engage in discussions with peers across all research areas.
AD/PD 2026 Conference Website. 2026. ↩︎
Huang Y, et al. APP processing and the amyloid hypothesis. Nat Rev Neurosci. 2023. 2023. ↩︎
Bridi JC, et al. Alpha-Synuclein: The Pathophysiology of a Cholinoceptive Synaptopodin Cytosolic Membrane Protein. Front Cell Dev Biol. 2023. 2023. ↩︎